RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy

References

• Lister-SharpD, McDonaghMS, KhanKS, KleijnenJ. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):1–113. doi:10.3310/hta4170
   Google Scholar
• MemarzadehS, BerekJS. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2001;46(7):621–629.11499181
   PubMed Web of Science ®Google Scholar
• BeersMH, BerkowR, editors. Ovarian cancer In: The Merck Manual of Diagnosis and Therapy. 17th Hitehouse Station, NJ: Merck Research Laboratories; 1999:1962–1964.
   Google Scholar
• NawazW, ZhouZ, DengS, et al. Therapeutic versatility of resveratrol derivatives. Nutrients. 2017;9(11):1188. doi:10.3390/nu9111188
   PubMed Web of Science ®Google Scholar
• KozukiY, MiuraY, YagasakiK. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett. 2001;167(2):151–156. doi:10.1016/S0304-3835(01)00476-111369135
   PubMed Web of Science ®Google Scholar
• OpipariAW, TanL, BoitanoAE, SorensonDR, AuroraA, LiuJR. Resveratrolinduced autophagocytosis in ovarian cancer cells. Cancer Res. 2004;64(2):696–703. doi:10.1158/0008-5472.CAN-03-240414744787
   PubMed Web of Science ®Google Scholar
• JangM, CaiL, UdeaniGO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218–220. doi:10.1126/science.275.5297.2188985016
   PubMed Web of Science ®Google Scholar
• GwakH, KimS, DhanasekaranDN, SongYS. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 2016;371(2):347–353. doi:10.1016/j.canlet.2015.11.03226704305
   PubMed Web of Science ®Google Scholar
• GelderblomH, VerweijJ, NooterK, SparreboomA. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–1598. doi:10.1016/S0959-8049(01)00171-X11527683
   PubMed Web of Science ®Google Scholar
• Ten TijeAJ, VerweijJ, LoosWJ, SparreboomA. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685. doi:10.2165/00003088-200342070-0000512844327
   PubMed Web of Science ®Google Scholar
• EmerichDF. Nanomedicine-prospective therapeutic and diagnostic applications. Expert Opin Biol Ther. 2005;5(1):1–5. doi:10.1517/14712598.5.1.115709905
   PubMed Web of Science ®Google Scholar
• WagnerV, DullaartA, BockAK, ZweckA. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10):1211–1217. doi:10.1038/nbt1006-121117033654
   PubMed Web of Science ®Google Scholar
• NieS, XingY, KimGJ, SimonsJW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257–288. doi:10.1146/annurev.bioeng.9.060906.15202517439359
   PubMed Web of Science ®Google Scholar
• MieleE, SpinelliGP, TomaoF, TomaoS, TomaoS. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99–105. doi:10.2147/ijn.s306119516888
   PubMed Web of Science ®Google Scholar
• GreenMR, ManikhasGM, OrlovS, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263–1268. doi:10.1093/annonc/mdl10416740598
   PubMed Web of Science ®Google Scholar
• GradisharWJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–1053. doi:10.1517/14656566.7.8.104116722814
   PubMed Web of Science ®Google Scholar
• StinchcombeTE, SocinskiMA, WalkoCM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol. 2007;60(5):759–766. doi:10.1007/s00280-007-0423-x17285317
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. V1; 2015 Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 316, 2015.
   Google Scholar
• DamascelliB, CantuG, MattavelliF, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92(10):2592–2602. doi:10.1002/1097-0142(20011115)92:10<2592::aid-cncr1612>3.0.co;2-411745194
   PubMed Web of Science ®Google Scholar
• ZhangL, HouSX, MaoSJ, WeiDP, SongXJ, LuY. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm. 2004;287(1–2):155–162. doi:10.1016/j.ijpharm.2004.08.01515541922
   PubMed Web of Science ®Google Scholar
• UlbrichK, HekmataraaT, HerbertaE, KreuterJ. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251–256. doi:10.1016/j.ejpb.2008.08.02118805484
   PubMed Web of Science ®Google Scholar
• AnuradhaCD, KannoS, HiranoS. RGD peptide-induced apoptosis in human leukemia HL-60 cells requires caspase-3 activation. Cell Biol Toxicol. 2000;16(5):275–283. doi:10.1023/A:102675842923811201051
   PubMed Web of Science ®Google Scholar
• MadejaZ, SrokaJ. Contact guidance of Walker carcinosarcoma cells by the underlying normal fibroblasts is inhibited by RGD-containing synthetic peptides. Folia Histochem Cytobiol. 2002;40(3):251–260.12219835
   PubMed Web of Science ®Google Scholar
• KangIC, KimDS, JangY, ChungKH. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem Biophys Res Commun. 2000;275(1):169–173. doi:10.1006/bbrc.2000.313010944460
   PubMed Web of Science ®Google Scholar
• CannistraSA, OttensmeierC, NiloffJ, OrtaB, DiCarloJ. Expression and function of β1 and avβ3 integrins in ovarian cancer. Gynecol Oncol. 1995;58(2):216–225. doi:10.1006/gyno.1995.12147542622
   PubMed Web of Science ®Google Scholar
• TomitaM, SugiH, OzawaK, TsongTY, YoshimuraT. Targeting antigen-specific receptors on B lymphocytes to generate high yields of specific monoclonal antibodies directed against biologically active lower antigenic peptides within presenilin 1. J Immunol Methods. 2001;251(1–2):31–43. doi:10.1016/S0022-1759(01)00299-X11292479
   PubMed Web of Science ®Google Scholar
• NamS, LeeSY, KangWS, ChoHJ. Development of resveratrol-loaded herbal extract-based nanocomposites and their application to the therapy of ovarian cancer. Nanomaterials (Basel). 2018;8(6):pii: E384. doi:10.3390/nano8060384
   Google Scholar
• ZhaoD. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomed. 2010;5:669–677.
   PubMed Web of Science ®Google Scholar
• GengT, ZhaoX, MaM, ZhuG, YinL. Resveratrol-loaded albumin nanoparticles with prolonged blood circulation and improved biocompatibility for highly effective targeted pancreatic tumor therapy. Nanoscale Res Lett. 2017;12(1):437. doi:10.1186/s11671-017-2206-628673056
   PubMed Web of Science ®Google Scholar
• NooraniL, StenzelM, LiangR, PourgholamiMH, MorrisDL. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. J Nanobiotechnology. 2015;13:25. doi:10.1186/s12951-015-0082-825890381
   PubMed Web of Science ®Google Scholar